Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 86% · fresh
- Computed at
- 2026-10-21T06:32:37.534186+00:00
- Claimed
- 80
- Reported
- 78
- Verified
- 73
- Gap
- +7
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Critical
Decision
What the current evidence supports
Human editorial judgment · 2026-10-21
Proceed with caution
- Why
- The approval is real, FDA-labelled and in market, and the data show a high response rate (79% ORR by independent review; 71% of 154 patients received dostarlimab alone with no progression). The evidence is a single-arm phase 2 with a wide efficacy gap between independent review (47% cCR12) and investigator assessment (68%), about 2 years of follow-up, and a small biomarker-defined population. This is a clinically significant, regulator-sanctioned option for a narrow group, but durability and relative benefit versus standard chemoradiation and surgery are not established.
- Next
- Review the full AZUR-1 interim data presented at ESMO (October 2026) and the Drugs@FDA label; track the sponsor's post-approval follow-up commitments and EU/UK/Canada/Swiss decisions under Project Orbis.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 8
- Tier 1
- 4
- Tier 2
- 4
- Tier 3
- 0
- Supports
- 3
- Contradicts
- 1
- Context
- 4
- Latest observed
- 2026-10-19
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
- 2026-10-21 Initial recorded band: ready.